UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and [...] Read more »
ATNi lança 5º Índice Global de Acesso à Nutrição enquanto a indústria e os formuladores de políticas lutam contra a policrise alimentar
UTRECHT, Países Baixos, Nov. 07, 2024 (GLOBE NEWSWIRE) — Hoje, a ATNi lança a 5a edição do Índice Global de Acesso à Nutrição, o maior até o momento, avaliando [...] Read more »
ATNi veröffentlicht den 5. Global Access to Nutrition Index, während sich Industrie und Politik mit der Nahrungsmittelkrise als Teil der weltweiten Polykrise auseinandersetzen
UTRECHT, Niederlande, Nov. 07, 2024 (GLOBE NEWSWIRE) — ATNi veröffentlicht heute die fünfte und bisher größte Ausgabe des Global Access to Nutrition Index, der die 30 größten Lebensmittel– und [...] Read more »
L’ATNi lance le 5e Indice mondial d’accès à la nutrition alors que l’industrie et les décideurs politiques sont aux prises avec la polycrise alimentaire
UTRECHT, Pays–Bas, 07 nov. 2024 (GLOBE NEWSWIRE) — Aujourd’hui, l’ATNi lance la 5e édition de l’Indice mondial d’accès à la nutrition, la plus importante à ce jour. [...] Read more »
Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical, Advocates Against Cyberbullying in Istanbul
ISTANBUL, Oct. 31, 2024 (GLOBE NEWSWIRE) — World–renowned cyberbullying activist Monica Lewinsky visited Istanbul this October at the invitation of Agnivesh Agarwal, founder of Primeks Medical Clinics and Laboratories. Her [...] Read more »
Advanced Care Group Makes a Strong Entrance at Global Health Exhibition, Ready to Lead at Arab Health 2025
RIYADH, Saudi Arabia, Oct. 25, 2024 (GLOBE NEWSWIRE) — Advanced Care Group is making waves in the Middle Eastern healthcare market following a powerful debut at the Global Health Exhibition in Riyadh. From October 21 to 23, Advanced [...] Read more »
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- REC–3964 is Recursion’s first new chemical entity developed using the RecursionOS.
- REC–3964 represents a novel, non–antibiotic approach with a unique mechanism of action that binds and blocks [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- First program to combine Recursion’s end–to–end suite of AI–enabled active learning modules, resulting in target identification to IND enabling studies in under [...] Read more »